WebPlease refer to the Israeli approved SmPC for Soliris, including information regarding serious meningococcal infection 2 IMPORTANT SAFETY INFORMATION1 Due to its mechanism of action, the use of SOLIRIS® increases the risk of severe infection and sepsis, especially meningococcal infection (Neisseria meningitidis) for the patient.The following steps must … WebEculizumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing. Consult product literature for details of supplemental doses with concomitant plasmapheresis, plasma exchange, or plasma infusion.
SOLIRIS® (eculizumab) Home Patient Site
WebDec 26, 2024 · The U.S. prescribing information for Soliris includes the following warnings and precautions: Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. WebFeb 26, 2015 · The organization's Canadian Drug Expert Committee recommended against funding Soliris in 2013, but Ms. McGurn said some new practices and evidence around the drug persuaded Ontario to ask for ... pmc courtroom 02
eculizumab Uses, Side Effects, Dosage & Interactions
WebAug 31, 2024 · The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection) pain or swelling of your nose or throat (nasopharyngitis) diarrhea. back pain. joint pain (arthralgia) throat irritation ( pharyngitis) bruising ( contusion) dizziness. WebIt’s our goal to support you and your loved ones throughout your treatment with SOLIRIS ® (eculizumab). The OneSource ™ support program is here to help you navigate your insurance coverage, understand your condition, and connect with others in the community. Take a look at the different types of personalized support available to you while taking … WebAug 27, 2024 · BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS ® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti … pmc compact boek